PepGen (NASDAQ:PEPG) Given “Buy” Rating at Guggenheim

Guggenheim reissued their buy rating on shares of PepGen (NASDAQ:PEPG) in a report issued on Wednesday,Benzinga reports. Guggenheim currently has a $6.00 target price on the stock.

Separately, HC Wainwright cut their price target on shares of PepGen from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, May 29th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, PepGen presently has a consensus rating of “Moderate Buy” and an average target price of $7.25.

PepGen Stock Performance

NASDAQ PEPG opened at $2.66 on Wednesday. PepGen has a one year low of $0.88 and a one year high of $9.94. The company’s 50 day moving average price is $1.42 and its 200 day moving average price is $1.45. The firm has a market capitalization of $87.25 million, a price-to-earnings ratio of -0.90 and a beta of 1.17.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.15. Sell-side analysts forecast that PepGen will post -2.73 EPS for the current fiscal year.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently made changes to their positions in PEPG. XTX Topco Ltd bought a new stake in shares of PepGen in the first quarter worth $25,000. ADAR1 Capital Management LLC bought a new stake in shares of PepGen in the first quarter worth $29,000. Rangeley Capital LLC increased its stake in shares of PepGen by 133.3% in the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after buying an additional 20,000 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of PepGen in the second quarter worth $44,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of PepGen in the second quarter worth $81,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.